Pilot study on the safety of swine immunoglobulin in dogs as a substitute for human intravenous immunoglobulin | Synapse
March 28, 2026Open Access
Pilot study on the safety of swine immunoglobulin in dogs as a substitute for human intravenous immunoglobulin
Key Points
The study aims to assess the safety of swine immunoglobulin (SwIgG) in dogs as an alternative to human intravenous immunoglobulin (IVIG).
Pilot study design focusing on SwIgG administration in dogs.
Monitoring of safety parameters and reactions post-administration.
Assessment of SwIgG's potential as an adjunctive treatment.
SwIgG is feasible for use in dogs without significant adverse effects discovered.
Suggests further investigations into its role in treating immune-mediated disorders.
Abstract
It is feasible to use SwIgG in dogs and additional studies to investigate its use as an adjunctive treatment for immune-mediated disorders are warranted.